Literature DB >> 16244115

Modulation of phenotype and function of dendritic cells by a therapeutic synthetic killer peptide.

Elio Cenci1, Eva Pericolini, Antonella Mencacci, Stefania Conti, Walter Magliani, Francesco Bistoni, Luciano Polonelli, Anna Vecchiarelli.   

Abstract

The strong microbicidal effects of an engineered synthetic killer peptide (KP), which functionally mimics a fungal killer toxin, have been demonstrated extensively. Beta-glucan has been identified as a receptor for KP on fungal cell walls. Although the direct microbicidal and related therapeutic effects have been studied in depth, no information currently exists about the interaction of KP with immune cells. In this study, we exploited the possibility of KP binding to different murine immune cell populations. The results demonstrate that KP binds selectively to dendritic cells (DC) and to a lesser extent, to macrophages but not to lymphocytes and neutrophils; KP binding possibly occurs through major histocompatibility complex (MHC) class II, CD16/32, and cellular molecules recognized by anti-specific intercellular adhesion molecule-grabbing nonintegrin R1 antibodies; and KP modulates the expression of costimulatory and MHC molecules on DC and improves their capacity to induce lymphocyte proliferation. These findings provide evidence that this synthetic KP interacts selectively with DC and modulating their multiple functions, might also serve to improve the immune antimicrobial response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16244115     DOI: 10.1189/jlb.0205113

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  6 in total

1.  Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection.

Authors:  Giorgio Conti; Walter Magliani; Stefania Conti; Lucia Nencioni; Rossella Sgarbanti; Anna Teresa Palamara; Luciano Polonelli
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

2.  Antibody complementarity-determining regions (CDRs): a bridge between adaptive and innate immunity.

Authors:  Elena Gabrielli; Eva Pericolini; Elio Cenci; Federica Ortelli; Walter Magliani; Tecla Ciociola; Francesco Bistoni; Stefania Conti; Anna Vecchiarelli; Luciano Polonelli
Journal:  PLoS One       Date:  2009-12-04       Impact factor: 3.240

3.  Peptides of the constant region of antibodies display fungicidal activity.

Authors:  Luciano Polonelli; Tecla Ciociola; Walter Magliani; Pier Paolo Zanello; Tiziana D'Adda; Serena Galati; Flavia De Bernardis; Silvia Arancia; Elena Gabrielli; Eva Pericolini; Anna Vecchiarelli; Denise C Arruda; Marcia R Pinto; Luiz R Travassos; Thelma A Pertinhez; Alberto Spisni; Stefania Conti
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

4.  Antibody Peptide based antifungal immunotherapy.

Authors:  Walter Magliani; Stefania Conti; Laura Giovati; Pier Paolo Zanello; Martina Sperindè; Tecla Ciociola; Luciano Polonelli
Journal:  Front Microbiol       Date:  2012-06-01       Impact factor: 5.640

5.  AC-1001 H3 CDR peptide induces apoptosis and signs of autophagy in vitro and exhibits antimetastatic activity in a syngeneic melanoma model.

Authors:  Aline N Rabaça; Denise C Arruda; Carlos R Figueiredo; Mariana H Massaoka; Camyla F Farias; Dayane B Tada; Vera C Maia; Pedro I Silva Junior; Natalia Girola; Fernando Real; Renato A Mortara; Luciano Polonelli; Luiz R Travassos
Journal:  FEBS Open Bio       Date:  2016-07-15       Impact factor: 2.693

6.  Antibody constant region peptides can display immunomodulatory activity through activation of the Dectin-1 signalling pathway.

Authors:  Elena Gabrielli; Eva Pericolini; Elio Cenci; Claudia Monari; Walter Magliani; Tecla Ciociola; Stefania Conti; Rita Gatti; Francesco Bistoni; Luciano Polonelli; Anna Vecchiarelli
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.